Contec announced today that it has contracted with Milliken & Company to help produce mass quantities of Contec’s Sporicidin brand disinfectant for infection control during the COVID-19 pandemic.
Since 1978, Sporicidin brand disinfectant products have been used for infection and contamination control by hospitals, medical and dental offices, veterinary clinics and restoration professionals, according to Spartanburg, S.C.-based Contec.
The EPA-registered intermediate-level disinfectant cleans, disinfects and deodorizes, and provides 100% kill of pathogenic vegetative organisms, including MRSA, VRE and Avian Influenza A Virus (H9N2 and H1N1) with continuous residual activity for up to six months, the company said. It is alcohol-free and compatible with plastics, wood, glass and metals. Sporicidin is also non-staining, non-abrasive and non-corrosive. It carries a Category IV EPA toxicity rating, the lowest toxicity rating given to antimicrobials.
Milliken, a diversified global manufacturer and materials science firm also headquartered in Spartanburg, began Sporicidin production on Tuesday, May 12, after a ramp-up of only four weeks.
“Milliken immediately came to mind when we decided to bring on a new manufacturing partner,” said Contec CEO Jack McBride in a news release. “Milliken is a trusted, key community player with the mass production, quality systems and speed-to-market capabilities needed to help us provide critical cleaning solutions to healthcare facilities without delay.”
“Companies are adapting their core competencies to meet the global challenges brought on by COVID-19,” added Milliken president & CEO Halsey M. Cook. “Partnering with Contec, Inc. was a natural fit, and gave Milliken the opportunity to quickly reconfigure our manufacturing capabilities and rapidly solve problems for our customers and communities.”
